Decentralized clinical trial (DCT) is an extension of traditional clinical trials to broader environments driven by digital technologies. DCTs can improve operative hurdles of clinical trials in more efficient manner and facilitate the acquisition of clinical data in real-world settings. These advantages were enabled by digital technologies including wearable and mobile devices and electronic consent. However, several DCT elements such as direct-to-patient shipping are not always implemented due to local regulations. Interventions evaluated in a DCT comprised not only conventional drug products but also novel approaches such as digital therapeutics. Currently, DCT is gaining attention in Korea but DCT cases have been relatively few compared to the United States or Europe. Collaborative working groups from the academic, industrial, and regulatory sectors has been recently established and tries to facilitate the DCT environment in Korea. We will discuss the role of clinical pharmacologists in this talk.